TriSalus Life Sciences, Inc. TLSI Derivative Liabilities - Fair Value
Derivative Liabilities - Fair Value at other companies
Other financials
Where this comes from
Reported directly by TriSalus Life Sciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about TriSalus Life Sciences, Inc.'s derivative liabilities - fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TriSalus Life Sciences, Inc.'s derivative liabilities - fair value?
- TriSalus Life Sciences, Inc. (TLSI) reported derivative liabilities - fair value of $9.08M in Q1 2026.
- How has TriSalus Life Sciences, Inc.'s derivative liabilities - fair value changed year-over-year?
- TriSalus Life Sciences, Inc.'s derivative liabilities - fair value decreased by 4.1% year-over-year, from $9.46M to $9.08M.
- What is the long-term trend for TriSalus Life Sciences, Inc.'s derivative liabilities - fair value?
- Over 3 years (2022 to 2025), TriSalus Life Sciences, Inc.'s derivative liabilities - fair value has grown at a -7.3% compound annual growth rate (CAGR), from $16.19M to $12.89M.
- What does derivative liabilities - fair value mean?
- This metric represents the total fair market value of all derivative contracts currently in a liability position for the institution. It reflects the potential cash outflow required if these contracts were settled at the current reporting date. Monitoring this value is essential for assessing the bank's exposure to market volatility and counterparty risk.